Discovery of common and rare genetic risk variants for colorectal cancer.

Nat Genet
Authors
Keywords
Abstract

To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P  5 × 10, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.

Year of Publication
2019
Journal
Nat Genet
Volume
51
Issue
1
Pages
76-87
Date Published
2019 Jan
ISSN
1546-1718
DOI
10.1038/s41588-018-0286-6
PubMed ID
30510241
PubMed Central ID
PMC6358437
Links
Grant list
P30 CA015704 / CA / NCI NIH HHS / United States
K01 DK110267 / DK / NIDDK NIH HHS / United States
P30 DK058404 / DK / NIDDK NIH HHS / United States
U01 CA164930 / CA / NCI NIH HHS / United States
U01 CA074794 / CA / NCI NIH HHS / United States
R01 CA207371 / CA / NCI NIH HHS / United States
P30 CA016058 / CA / NCI NIH HHS / United States
K05 CA152715 / CA / NCI NIH HHS / United States
S10 OD020069 / OD / NIH HHS / United States
MR/L01629X/1 / MRC_ / Medical Research Council / United Kingdom
P01 CA196569 / CA / NCI NIH HHS / United States
10119 / CRUK_ / Cancer Research UK / United Kingdom
U19 CA148107 / CA / NCI NIH HHS / United States
10589 / CRUK_ / Cancer Research UK / United Kingdom
R01 CA059045 / CA / NCI NIH HHS / United States
R01 CA197350 / CA / NCI NIH HHS / United States
10124 / CRUK_ / Cancer Research UK / United Kingdom
R35 CA197735 / CA / NCI NIH HHS / United States
P30 ES010126 / ES / NIEHS NIH HHS / United States
R01 CA204279 / CA / NCI NIH HHS / United States
U10 CA037429 / CA / NCI NIH HHS / United States
U01 CA182883 / CA / NCI NIH HHS / United States
R01 CA160356 / CA / NCI NIH HHS / United States
UG1 CA189974 / CA / NCI NIH HHS / United States
R01 CA189184 / CA / NCI NIH HHS / United States
U01 CA137088 / CA / NCI NIH HHS / United States
K23 DK103119 / DK / NIDDK NIH HHS / United States
U24 CA074794 / CA / NCI NIH HHS / United States
R21 CA191312 / CA / NCI NIH HHS / United States
U01 CA206110 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
10822 / CRUK_ / Cancer Research UK / United Kingdom
U01 CA167551 / CA / NCI NIH HHS / United States
U01 CA185094 / CA / NCI NIH HHS / United States
P30 CA014089 / CA / NCI NIH HHS / United States
R01 CA081488 / CA / NCI NIH HHS / United States
R01 CA143237 / CA / NCI NIH HHS / United States
R01 CA201407 / CA / NCI NIH HHS / United States
UM1 CA182883 / CA / NCI NIH HHS / United States
HHSN268201200008I / HL / NHLBI NIH HHS / United States
U01 CA152756 / CA / NCI NIH HHS / United States
R01 CA193677 / CA / NCI NIH HHS / United States